

# STAR SOURCE MULTITRADE LIMITED

(Formerly known as *Chemo Pharm Laboratories Limited*)

(CIN: L46900MH1942PLC003556)

**Registered Office:** 5-Kumud Apartment Co. Op. HSG. SOC. Ltd, Karnik Road, Chikan Ghar, Kalyan, Dist. Thane – 421301

**Corporate Office:** Office No 1016, North Plaza, Near D Mart, Visat Gandhinagar Highway, Motera, Ahmedabad, Gujarat, India – 380005

Tel. No.:022-22078382 Website: [www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)  
Email : [chemopharmalaboratorieslimited@gmail.com](mailto:chemopharmalaboratorieslimited@gmail.com)

Date: February 12, 2026

To,  
Bombay Stock Exchange Limited  
Department of Corporate Services,  
25th Floor, P. J. Towers, Dalal Street,  
Mumbai-400001

**Script Id: 506365**

**ISIN: INE320M01019**

**Subject: Outcome of Board Meeting held on Thursday, February 12, 2026.**

Dear Sir / Madam,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that Board of Directors of the Company at their meeting held on Thursday, **February 12, 2026** at the Registered Office of the Company, inter alia, have considered and approved the following:

1. Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2025.
2. Limited Review Report on the Un-audited Financial Results of the Company for the quarter ended on December 31, 2025.

The Un-audited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2025 along with the limited review reports thereon are enclosed herewith.

The aforesaid information is also available on website of the company.

The meeting commenced at 12:00 PM and concluded at **12:45 PM.**

The same may please be taken on record.

Thanking You.  
Yours Faithfully,

FOR STAR SOURCE MULTITRADE LIMITED  
(Formerly known as CHEMO PHARMA LABORATORIES LIMITED)



RUCHIT MEHTA  
Managing Director & Chief Executive Officer  
DIN: 08810586

**Independent Auditor, Review Report on Unaudited Standalone Financial Results for the quarter and Nine Month ended 31st December, 2025 of STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED) pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 (2) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended.**

To,  
 The Board of Directors,  
**STARSOURCE MULTITRADE LIMITED**  
 (Formerly known as **CHEMO PHARMA LABORATORIES LIMITED**)

1. We have reviewed the accompanying statements of unaudited IND-AS Financial Results of **STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED)** ('the Company") for the quarter and Nine Month ended 31<sup>st</sup> December, 2025 ("The Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Director's, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in compliance with Listing Obligations. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S S R V & Associates**

Chartered Accountants



Vishnu Kant Kabra

Partner

M. No.: 403437

Place: Mumbai

Date: 12<sup>th</sup> February, 2026

UDIN: 26403437SJGEN4781

**STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED)**  
**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2025**  
(Rupees in Thoudsand)

Sr. No	Particulars	Quarter ended			Nine Months Ended		Year ended
		31st Dec 2025	30th Sep 2025	31st Dec 2024	31st Dec 2025	31st Dec 2024	31st March 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	0.00	5256.56	0.00	5256.56	0.00	0.00
II	Other income	0.00	0.00	(1488.00)	207.12	7839.00	6198.00
III	<b>TOTAL REVENUE</b>	<b>0.00</b>	<b>5256.56</b>	<b>(1488.00)</b>	<b>5463.68</b>	<b>7839.00</b>	<b>6198.00</b>
IV	<b>EXPENSES</b>						
	(1) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Purchases of stock-in-trade	0.00	3765.35	0.00	3765.35	0.00	0.00
	(3) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(4) Employee benefits expense	216.00	216.00	54.00	672.60	177.00	216.00
	(5) Finance costs	0.00	0.59	0.00	5.97	0.00	0.00
	(6) Depreciation and amortisation expense	0.00	0.00	14.00	0.00	41.00	54.00
	(7) Administrative & Other expenses	649.11	294.48	192.00	118955.38	803.00	947.00
	<b>TOTAL EXPENSES</b>	<b>865.11</b>	<b>4276.42</b>	<b>260.00</b>	<b>123399.30</b>	<b>1021.00</b>	<b>1217.00</b>
V	Profit/(Loss) before exceptional items & tax	(865.11)	980.14	(1748.00)	(117935.62)	6818.00	4981.00
VI	Exceptional items (net charge)	0.00	0.00	0.00	0.00	0.00	0.00
VII	Net Profit before ExtraOrdinary Items & Tax	(865.11)	980.14	(1748.00)	(117935.62)	6818.00	4981.00
VIII	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Profit before Tax</b>	<b>(865.11)</b>	<b>980.14</b>	<b>(1748.00)</b>	<b>(117935.62)</b>	<b>6818.00</b>	<b>4981.00</b>
X	<b>Tax Expenses</b>						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	1993.00
	(2) Tax Aduugment Previous Year	0.00	0.00	0.00	0.00	0.00	0.00
	(3) Deferred tax credit/(charge)	0.00	0.00	0.00	0.00	0.00	(435.00)
	(4) MAT Credit Entitlement	0.00	0.00	0.00	0.00	0.00	0.00
XI	<b>PROFIT/Loss FOR THE PERIOD from continious operations</b>	<b>(865.11)</b>	<b>980.14</b>	<b>(1748.00)</b>	<b>(117935.62)</b>	<b>6818.00</b>	<b>3423.00</b>
XII	PROFIT/Loss from dis-continious operations	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Tax expenses for dis-continious operations	0.00	0.00	0.00	0.00	0.00	0.00
XIV	PROFIT/Loss FOR THE PERIOD from dis-continious operations	0.00	0.00	0.00	0.00	0.00	0.00
XV	<b>PROFIT/Loss FOR THE PERIOD</b>	<b>(865.11)</b>	<b>980.14</b>	<b>(1748.00)</b>	<b>(117935.62)</b>	<b>6818.00</b>	<b>3423.00</b>
XVI	<b>OTHER COMPREHENSIVE INCOME</b>						
	A(i)Items that will not be reclassified subsequently to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified subsequently to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XVII	<b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (Comprising Profit/(Loss) and other comprehensive income for the period</b>	<b>(865.11)</b>	<b>980.14</b>	<b>(1748.00)</b>	<b>(117935.62)</b>	<b>6818.00</b>	<b>3423.00</b>
XVIII	Earnings per equity share						
	(1) Basic	-0.58	0.65	-1.17	-78.62	4.55	2.28
	(2) Diluted	-0.58	0.65	-1.17	-78.62	4.55	2.28

FOR STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED)

Date: 12.02.2026

Place: Mumbai



RUCHIT MEHTA  
MD & CEO  
DIN: 08810586

**Notes:**

1. This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies . (Indian Accounting Standard) Accounting Rules, 2016.
2. The above Standalone Unaudited Financial Results for the Quarter & Nine Months Ended 31.12.2025 have been reviewed by the Audit Committee in their Meeting held on 12.02.2026 and approved by the Board of Directors of its Meeting held on 12.02.2026. The Limited Review Report of Auditors M/s S S R V & Associates was also taken on record by the Board in its Meeting.
- 3 The Company is not having any Subsidiary Company.
- 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

FOR STARSOURCE MULTITRADE LIMITED  
(Formerly known as CHEMO PHARMA  
LABORATORIES LIMITED)

Date: 12.02.2026

Place: Mumbai



RUCHIT MEHTA  
MD & CEO  
DIN: 08810586

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

(Rs. In Thousands)

PARTICULARS	STANDALONE					AUDITED YEAR ENDED  31.12.2025	
	UNAUDITED QUARTER ENDED			UNAUDITED NINE MONTHS ENDED			
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024		
<b>Reconciliation of Profit After Tax as reported earlier:</b>							
Net Profit / (Loss) for the Period (as per AS)	<b>-865.11</b>	980.14	1,210.00	<b>-1,18,142.14</b>	4,533.00	<b>-1,837.00</b>	
Benefit / (Charge):							
Impact of Deferred Income (Government Grant) Amortized to Income	0.00	0.00	0.00	0.00	0.00	0.00	
Impact of Fair Valuation of Financial Instruments	0.00	0.00	<b>-2,958.00</b>	1,16,595.65	2,285.00	1,993.00	
Impact of Actuarial Gain / Loss Taken OCI	0.00	0.00	0.00	0.00	0.00	0.00	
Impact of Adjustment of Deferred Tax	0.00	0.00	0.00	0.00	0.00	<b>-435.00</b>	
Impact of Adjustment of MAT Credit Entitlement	0.00	0.00	0.00	0.00	0.00	0.00	
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>-865.11</b>	<b>980.14</b>	<b>-1,748.00</b>	<b>-1,546.49</b>	<b>6,818.00</b>	<b>-3,396.00</b>	

**OTHER INFORMATION- INTEGRATED FILING (FINANCIAL) -  
FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2025**

(In accordance with the SEBI circular no . SEBI/ HO/ CFD/CFD-PoD-2/CIR/P/185 dated December 31, 2024)

<b>Sr. No</b>	<b>Particulars</b>	<b>Remarks</b>
1	B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.	NOT APPLICABLE
2	C. Format for disclosing outstanding default on loans and debt securities	NOT APPLICABLE
3	D. Format for disclosure of related party transactions (applicable only for half yearly filings i.e. , 2nd and 4th quarter)	NOT APPLICABLE
4	E. Statement on impact of audit qualifications (for audit report with modified opinion ) submitted along-with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter)	NOT APPLICABLE

FOR STARSOURCE MULTITRADE LIMITED  
(Formerly known as CHEMO PHARMA LABORATORIES LIMITED)

Date: 12.02.2026

Place: Mumbai



RUCHIT MEHTA  
MD & CEO  
DIN: 08810586